| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/JMCC.1998.0721 |
| P698 | PubMed publication ID | 9737942 |
| P2093 | author name string | Zhang J | |
| Sun Y | |||
| Zhang JQ | |||
| Ramires FJ | |||
| P433 | issue | 8 | |
| P304 | page(s) | 1559-1569 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | Journal of Molecular and Cellular Cardiology | Q2061932 |
| P1476 | title | Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart | |
| P478 | volume | 30 |
| Q50769739 | A 7.1 kbp beta-myosin heavy chain promoter, efficient for green fluorescent protein expression, probably induces lethality when overexpressing a mutated transforming growth factor-beta type II receptor in transgenic mice. |
| Q33705086 | A Mouse Strain Where Basal Connective Tissue Growth Factor Gene Expression Can Be Switched from Low to High |
| Q50992929 | A single injection of protein-loaded coacervate-gel significantly improves cardiac function post infarction. |
| Q36929414 | ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis |
| Q33840689 | Ac-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts into myofibroblasts |
| Q40454979 | Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. |
| Q41838704 | Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction |
| Q48482592 | Activation of proinflammatory mediators in heart transplants from brain-dead donors: evidence from a model of chronic rat cardiac allograft rejection |
| Q52965082 | Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. |
| Q35214052 | Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone |
| Q51648646 | Alterations in plasma angiogenic growth factor concentrations after coronary artery bypass graft surgery: relationships with post-operative complications |
| Q33718262 | Angiotensin II and connective tissue: homeostasis and reciprocal regulation |
| Q35791591 | Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways |
| Q30304510 | Angiotensin II receptor blockers: review of the binding characteristics |
| Q34028682 | Angiotensin II sustains brain inflammation in mice via TGF-beta |
| Q53560212 | Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction. |
| Q35354025 | Angiotensin-converting enzyme-2 overexpression improves atrial remodeling and function in a canine model of atrial fibrillation |
| Q26745841 | Antifibrotic therapies to control cardiac fibrosis |
| Q34559487 | Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. |
| Q35811007 | Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats |
| Q42874872 | Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy |
| Q43515052 | Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats |
| Q30528431 | Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. |
| Q37221281 | Cardiac oxidative stress and remodeling following infarction: role of NADPH oxidase |
| Q35075553 | Cardiac remodeling and physical training post myocardial infarction |
| Q35567569 | Clinical implications of matrix metalloproteinases |
| Q40514223 | Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction |
| Q35588665 | Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins |
| Q33595504 | Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure |
| Q46594641 | Editorial commentary: Endothelial-to-mesenchymal transition: When the good one goes bad. |
| Q44629578 | Effect of propranolol on cardiac cytokine expression after myocardial infarction in rats |
| Q46634232 | Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats |
| Q43072994 | Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). |
| Q36462593 | Effects of exercise training on cardiac function and myocardial remodeling in post myocardial infarction rats |
| Q36203050 | Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms |
| Q35955262 | Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology |
| Q36455977 | Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia |
| Q50098773 | Fibrosis-Related Gene Expression in Single Ventricle Heart Disease |
| Q90536651 | Flavonoid Extract from Propolis Inhibits Cardiac Fibrosis Triggered by Myocardial Infarction through Upregulation of SIRT1 |
| Q36740263 | Hepatocyte growth factor regulates angiotensin converting enzyme expression |
| Q33999588 | Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade |
| Q36310106 | Improving vagal activity ameliorates cardiac fibrosis induced by angiotensin II: in vivo and in vitro |
| Q35099157 | Inflammation and angiotensin II. |
| Q38631821 | Integrins and integrin-related proteins in cardiac fibrosis |
| Q37580070 | Intracardiac renin-angiotensin system and myocardial repair/remodeling following infarction |
| Q42043098 | Kidney fibrosis in hypertensive rats: role of oxidative stress |
| Q37578873 | Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases |
| Q91229323 | Mechanical regulation of gene expression in cardiac myocytes and fibroblasts |
| Q47637496 | Mitral Leaflet Changes Following Myocardial Infarction: Clinical Evidence for Maladaptive Valvular Remodeling |
| Q28553085 | Myocardial Structural and Biological Anomalies Induced by High Fat Diet in Psammomys obesus Gerbils |
| Q35636517 | Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system |
| Q34892788 | Myocardial repair/remodelling following infarction: roles of local factors |
| Q64989426 | Myofibroblast modulation of cardiac myocyte structure and function. |
| Q38294134 | Myofibroblast secretome and its auto-/paracrine signaling |
| Q38064729 | Myofibroblast-mediated mechanisms of pathological remodelling of the heart |
| Q37972978 | Myofibroblasts in the infarct area: concepts and challenges |
| Q37772650 | New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies |
| Q47365279 | New methodologies to accurately assess circulating active transforming growth factor-β1 levels: implications for evaluating heart failure and the impact of left ventricular assist devices |
| Q37883418 | Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure |
| Q29347051 | Platelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts |
| Q35099164 | RAS and connective tissue in the heart |
| Q35564174 | Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist |
| Q91334860 | Reduction of cardiac TGFβ-mediated profibrotic events by inhibition of Hsp90 with engineered protein |
| Q89819882 | Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease |
| Q42703010 | Serum transforming growth factor-beta1 as a risk stratifier of sudden cardiac death |
| Q39155183 | TGF-β Family Signaling in Connective Tissue and Skeletal Diseases |
| Q38196176 | Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs. |
| Q37100838 | Targeting inflammatory pathways in myocardial infarction. |
| Q43036719 | Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy |
| Q41669775 | The Role of Endoglin in Myocardial Fibrosis |
| Q89623456 | The Role of the Renin-Angiotensin System and Vitamin D in Keloid Disorder-A Review |
| Q37096652 | The immune system and cardiac repair. |
| Q36655326 | The role of TGF-beta signaling in myocardial infarction and cardiac remodeling |
| Q38034004 | The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction |
| Q35580139 | Toward a broader understanding of aldosterone in congestive heart failure |
| Q36915712 | Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver. |
| Q35099152 | Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system |
| Q37808014 | Transforming growth factor (TGF)-β signaling in cardiac remodeling. |
| Q74317109 | Unchanged cardiac angiotensin II levels accompany losartan-sensitive cardiac injury due to nitric oxide synthase inhibition |
| Q36773118 | Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction |
| Q37629218 | Vascular endothelial growth factor-C: its unrevealed role in fibrogenesis |
| Q39413020 | miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling |
Search more.